{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004575","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.832538+00:00","generated_at":"2026-06-06T11:07:34.155736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evofem reports record Phexxi net sales of $18.1-$18.3M for FY2023, operating expense down >60%","bullets":["Preliminary 2023 net product sales of $18.1-$18.3M, third consecutive year of Phexxi revenue growth.","Total operating expense reduced by more than 60% from 2022 levels; loss from operations improved >75%.","Net product sales exceeded sales and marketing expense for 2023, key milestone.","Definitive agreement to be acquired by Aditxt (ADTX) remains on track for mid-2024 close."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004575","json":"https://secwatch.observer/filing/0001493152-24-004575.json","markdown":"https://secwatch.observer/filing/0001493152-24-004575.md","text":"https://secwatch.observer/filing/0001493152-24-004575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224004575/0001493152-24-004575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224004575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:07:34.155736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1b225246918ff83c4b9cb8153586b1af997691c","claim":"Evofem Biosciences, Inc. reported fiscal year ended December 31, 2023 results: revenue preliminary net product sales in the range of $18.1 to $18.3 million.","evidence_excerpt":"contraceptive gel, and the Company’s lowest total operating expenses since becoming a commercial stage company in 2020. ● Achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023. ● Company reached a key milestone","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224004575/0001493152-24-004575-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Revenue","value":"preliminary net product sales in the range of $18.1 to $18.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}